Physician profile
Joel Meshulam
NPI 1871513697
$3,321.53
in general payments reported to CMS, 2019-2025
31 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $147 · 2021: $370 · 2022: $272 · 2023: $707 · 2024: $714 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.93 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.98 | 2021-2025 | |
| Novo Nordisk INC | $393.67 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $309.75 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $269.06 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $228.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $221.62 | 2023-2025 | |
| Pfizer INC. | $194.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $165.32 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $124.50 | 2022-2025 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.09 | 2021-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $80.04 | 2023-2025 | Sunosi, Auvelity |
| Idorsia Pharmaceuticals US INC | $78.03 | 2023 | Quviviq |
| Abbott Laboratories | $65.73 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $61.32 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $58.96 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.52 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $44.76 | 2020-2022 | |
| Amarin Pharma, INC. | $44.73 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $31.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.05 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $25.44 | 2021 | |
| Almatica Pharma LLC | $22.38 | 2021 | |
| Ibsa Pharma INC. | $22.23 | 2023 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $21.95 | 2023 | Ingrezza |
| Sanofi Pasteur INC. | $21.43 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $17.08 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $16.87 | 2023 | Krystexxa |
| Tms Neurohealth Centers INC. | $15.45 | 2025 | Tms Neurohealth Centers INC. |
| Currax Pharmaceuticals LLC | $13.20 | 2023 | Contrave, Onzetra Xsail |
| Allergan, INC. | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Meshulam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.